The Pharmacological Properties and Therapeutic Use of Bitter Melon (Momordica charantia L.)

[1]  M. Slevin,et al.  Momordica charantia extracts protect against inhibition of endothelial angiogenesis by advanced glycation endproducts in vitro. , 2018, Food & function.

[2]  Shaobai Wang,et al.  The Most Commonly Treated Acupuncture Indications in the United States: A Cross-Sectional Study. , 2018, The American journal of Chinese medicine.

[3]  M. Raish,et al.  Momordica charantia polysaccharides ameliorate oxidative stress, inflammation, and apoptosis in ethanol-induced gastritis in mucosa through NF-kB signaling pathway inhibition. , 2018, International journal of biological macromolecules.

[4]  G. Sung,et al.  Momordica charantia Inhibits Inflammatory Responses in Murine Macrophages via Suppression of TAK1. , 2018, The American journal of Chinese medicine.

[5]  Chi-Tang Ho,et al.  Momordica charantia: a popular health-promoting vegetable with multifunctionality. , 2017, Food & function.

[6]  Jianhua Xie,et al.  A mini-review of chemical and biological properties of polysaccharides from Momordica charantia. , 2016, International journal of biological macromolecules.

[7]  Hsin-Yi Lo,et al.  Identification of the bioactive and consensus peptide motif from Momordica charantia insulin receptor-binding protein. , 2016, Food chemistry.

[8]  C. Gan,et al.  Polysaccharide with antioxidant, α-amylase inhibitory and ACE inhibitory activities from Momordica charantia. , 2016, International journal of biological macromolecules.

[9]  Zhen-Jie Li,et al.  Two New Cucurbitane Triterpenoids from Immature Fruits of Momordica charantia , 2015 .

[10]  S. S. Islam,et al.  Pectic polysaccharide from the green fruits of Momordica charantia (Karela): structural characterization and study of immunoenhancing and antioxidant properties. , 2015, Carbohydrate research.

[11]  T. Tulika,et al.  Therapeutic Efficacy of Centella asiatica (L.) and Momordica charantia: As Traditional Medicinal Plant , 2014 .

[12]  Ruifen Zhang,et al.  Immunomodulatory Activity and Partial Characterisation of Polysaccharides from Momordica charantia , 2014, Molecules.

[13]  E. Kennelly,et al.  Transport in Caco-2 Cell Monolayers of Antidiabetic Cucurbitane Triterpenoids from Momordica charantia Fruits , 2014, Planta Medica.

[14]  Shonima Talapatra,et al.  Molecular characterization, modeling and expression analysis of a somatic embryogenesis receptor kinase (SERK) gene in Momordica charantia L. during somatic embryogenesis , 2014, Plant Cell, Tissue and Organ Culture (PCTOC).

[15]  R. Ray,et al.  Bitter Melon Reduces Head and Neck Squamous Cell Carcinoma Growth by Targeting c-Met Signaling , 2013, PloS one.

[16]  Ting-feng Wu,et al.  Altered White Adipose Tissue Protein Profile in C57BL/6J Mice Displaying Delipidative, Inflammatory, and Browning Characteristics after Bitter Melon Seed Oil Treatment , 2013, PloS one.

[17]  E. Moran,et al.  Methanolic Extracts of Bitter Melon Inhibit Colon Cancer Stem Cells by Affecting Energy Homeostasis and Autophagy , 2013, Evidence-based complementary and alternative medicine : eCAM.

[18]  Lingxiao Guan.  Synthesis and anti-tumour activities of sulphated polysaccharide obtained from Momordica charantia , 2012, Natural Product Research.

[19]  T. Ng,et al.  RNase MC2: a new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of MAPKs and induction of caspase pathways , 2012, Apoptosis.

[20]  Wei-Hsiung Yang,et al.  Bitter melon (Momordica charantia) extract suppresses adrenocortical cancer cell proliferation through modulation of the apoptotic pathway, steroidogenesis, and insulin-like growth factor type 1 receptor/RAC-α serine/threonine-protein kinase signaling. , 2012, Journal of medicinal food.

[21]  Shuzhen Wang,et al.  Molecular cloning and functional analysis of a recombinant ribosome-inactivating protein (alpha-momorcharin) from Momordica charantia , 2012, Applied Microbiology and Biotechnology.

[22]  Pornsiri Pitchakarn,et al.  Induction of G1 arrest and apoptosis in androgen-dependent human prostate cancer by Kuguacin J, a triterpenoid from Momordica charantia leaf. , 2011, Cancer letters.

[23]  S. Babu,et al.  Influence of Momordica charantia on oxidative stress-induced perturbations in brain monoamines and plasma corticosterone in albino rats , 2011, Indian journal of pharmacology.

[24]  P. Williams,et al.  Momordica charantia (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation , 2011, Journal of Neuroinflammation.

[25]  A. S. Bawa,et al.  Studies on the antioxygenic activity of bitter gourd (Momordica charantia) and its fractions using various in vitro models. , 2011, Journal of the science of food and agriculture.

[26]  D. Feinstein,et al.  The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes , 2011, Journal of Neuroinflammation.

[27]  D. Chandra,et al.  Anti-hyperglycemic and anti-oxidative effect of aqueous extract of Momordica charantia pulp and Trigonella foenum graecum seed in alloxan-induced diabetic rats. , 2010, Indian journal of biochemistry & biophysics.

[28]  P. Chaturvedi,et al.  Momordica charantia maintains normal glucose levels and lipid profiles and prevents oxidative stress in diabetic rats subjected to chronic sucrose load. , 2010, Journal of medicinal food.

[29]  Wei Zhang,et al.  Bitter melon (Momordica charantia) triterpenoid extract reduces preadipocyte viability, lipid accumulation and adiponectin expression in 3T3-L1 cells. , 2010, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[30]  R. Ray,et al.  Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. , 2010, Cancer research.

[31]  V. Gupta,et al.  Momordica charantia trypsin inhibitor II inhibits growth and development of Helicoverpa armigera , 2009 .

[32]  A. Ray,et al.  Eleostearic Acid Inhibits Breast Cancer Proliferation by Means of an Oxidation-Dependent Mechanism , 2009, Cancer Prevention Research.

[33]  A. Levine,et al.  Ribosome‐inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase‐1 selectively in premalignant and malignant prostate cancer cells , 2009, International journal of cancer.

[34]  M. Kobori,et al.  Alpha-eleostearic acid and its dihydroxy derivative are major apoptosis-inducing components of bitter gourd. , 2008, Journal of agricultural and food chemistry.

[35]  Chi-I Chang,et al.  A cell-based screening identifies compounds from the stem of Momordica charantia that overcome insulin resistance and activate AMP-activated protein kinase. , 2008, Journal of agricultural and food chemistry.

[36]  L. Ng,et al.  Antioxidant and free radical scavenging activities of wild bitter melon (Momordica charantia Linn. var. abbreviata Ser.) in Taiwan , 2008 .

[37]  Alessandra Braca,et al.  Chemical composition and antimicrobial activity of Momordica charantia seed essential oil. , 2008, Fitoterapia.

[38]  Yongtang Zheng,et al.  Trinorcucurbitane and cucurbitane triterpenoids from the roots of Momordica charantia. , 2008, Phytochemistry.

[39]  S. Naik,et al.  An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized Momordica charantia fruit extract , 2007, BMC complementary and alternative medicine.

[40]  Harukuni Tokuda,et al.  Cucurbitane-type triterpenoids from the fruits of Momordica charantia and their cancer chemopreventive effects. , 2007, Journal of natural products.

[41]  P. Rao,et al.  The reparative effects of Momordica Charantia Linn. extract on HIT-T15 pancreatic beta-cells. , 2007, Asia Pacific journal of clinical nutrition.

[42]  H. Matsuda,et al.  Structures of new cucurbitane-type triterpenes and glycosides, karavilagenins and karavilosides, from the dried fruit of Momordica charantia L. in Sri Lanka. , 2006, Chemical & pharmaceutical bulletin.

[43]  Y. Kuo,et al.  Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARalpha in bitter gourd (Momordica charantia L.). , 2006, Journal of biomedical science.

[44]  M. Krawinkel,et al.  Bitter gourd (Momordica Charantia): A dietary approach to hyperglycemia. , 2006, Nutrition reviews.

[45]  S. Adisakwattana,et al.  Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. , 2006, Biological & pharmaceutical bulletin.

[46]  N. Hettiarachchy,et al.  Total Phenolic Contents and Phenolic Acid Constituents in 4 Varieties of Bitter Melons (Momordica charantia) and Antioxidant Activities of their Extracts , 2006 .

[47]  Qixuan Chen,et al.  Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression. , 2005, The Journal of nutrition.

[48]  P. Salimath,et al.  Effect of Bitter Gourd (Momordica charantia) on Glycaemic Status in Streptozotocin Induced Diabetic Rats , 2005, Plant foods for human nutrition.

[49]  Tomohiko Nakamura,et al.  Induction of Interferon-Gamma (IFN-γ) and T Helper 1 (Th1) Immune Response by Bitter Gourd Extract , 2005 .

[50]  Qixuan Chen,et al.  Reduced adiposity in bitter melon (Momordica charantia) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines. , 2005, The British journal of nutrition.

[51]  J. Hudson,et al.  Ethnomedicinal uses of Momordica charantia (Cucurbitaceae) in Togo and relation to its phytochemistr , 2005 .

[52]  J. Grover,et al.  Pharmacological actions and potential uses of Momordica charantia: a review. , 2004, Journal of ethnopharmacology.

[53]  H. Wackerhage,et al.  Momordica charantia fruit juice stimulates glucose and amino acid uptakes in L6 myotubes , 2004, Molecular and Cellular Biochemistry.

[54]  C. Chao,et al.  Bitter Gourd (Momordica charantia) Extract Activates Peroxisome Proliferator-Activated Receptors and Upregulates the Expression of the Acyl CoA Oxidase Gene in H4IIEC3 Hepatoma Cells , 2003, Journal of Biomedical Science.

[55]  E. Basch,et al.  Bitter melon (Momordica charantia): a review of efficacy and safety. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[56]  M. Manabe,et al.  Induction of Anti-inflammatory Responses by Dietary Momordica charantia L. (Bitter Gourd) , 2003, Bioscience, biotechnology, and biochemistry.

[57]  B. Şener,et al.  Anti-ulcerogenic effect of Momordica charantia L. fruits on various ulcer models in rats. , 2000, Journal of ethnopharmacology.

[58]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[59]  Jaipaul Singh,et al.  Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat. , 1998, Diabetes research and clinical practice.

[60]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[61]  H. Yeung,et al.  A steryl glycoside fraction from Momordica charantia seeds with an inhibitory action on lipid metabolism in vitro. , 1986, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[62]  Gerard G. Dumancas,et al.  Health Benefits of Bitter Melon (Momordica charantia) , 2010 .

[63]  Yong-tang Zheng,et al.  Kuguacins F-S, cucurbitane triterpenoids from Momordica charantia. , 2009, Phytochemistry.

[64]  Chen Hong-man.  Study on Seperation, Purification and Biological Activity for Soluble Polysaccharide from Momordica charantia , 2006 .

[65]  H. Matsuda,et al.  Medicinal foodstuffs. XXI. Structures of new cucurbitane-type triterpene glycosides, goyaglycosides-a, -b, -c, -d, -e, -f, -g, and -h, and new oleanane-type triterpene saponins, goyasaponins I, II, and III, from the fresh fruit of Japanese Momordica charantia L. , 2001, Chemical & pharmaceutical bulletin.

[66]  K. Platel,et al.  Plant foods in the management of diabetes mellitus: vegetables as potential hypoglycaemic agents. , 1997, Die Nahrung.